Literature DB >> 36181055

Cytokine-polymorphisms associated with Preeclampsia: A review.

Carlos Mora-Palazuelos1, Mercedes Bermúdez2, Maribel Aguilar-Medina3, Rosalío Ramos-Payan3, Alfredo Ayala-Ham1, Jose Geovanni Romero-Quintana3.   

Abstract

BACKGROUND: Preeclampsia (PE) is a syndromic disorder that affects 2% to 8% of pregnancies and is diagnosed principally when hypertension appears in the second-d half of pregnancy. WHO estimates the incidence of PE to be seven times higher in developing countries than in developed countries. Severe preeclampsia/eclampsia is one of the most important causes of maternal mortality, associated with 50,000 to 100,000 annual deaths globally as well as serious fetal and neonatal morbidity and mortality, especially in developing countries. Even though evidence from family-based studies suggest PE has a heritable component, its etiology, and specific genetic contributions remain unclear. Many studies examining the genetic factors contributing to PE have been conducted, most of them are focused on single nucleotide polymorphisms (SNPs). Given that PE has a very important inflammatory component, is mandatory to examine cytokine-SNPs for elucidating all mechanisms involved in this pathology. In this review, we describe the most important cytokine-polymorphisms associated with the onset and development of PE. We aim to provide current and relevant evidence in this regard.
METHODS: We searched English databases such as PubMed and the National Center for Biotechnology Information. The publication time of the papers was set from the establishment of the databases to February 2022. All studies about Th1/Th2/Th17 cytokines polymorphisms were included in our study.
RESULTS: SNPs in IFN-γ, TNF-α, IL-4, IL-6, IL-10, IL-17A, and IL-22 are associated with the development, early-onset and severity of PE, being the Th1/Th2/Th17 responses affected by the presence of these SNPs.
CONCLUSIONS: The changes in Th1/Th2/Th17 response modify processes such as placentation, control of inflammation, and vascular function. Nonetheless, association studies have shown different results depending on sample size, diagnostic, and population.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36181055      PMCID: PMC9524891          DOI: 10.1097/MD.0000000000030870

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


1. Introduction

Preeclampsia (PE) is a syndromic disorder that affects 2% to 8% of pregnancies and is diagnosed when hypertension appears in the second half of pregnancy.[ World Health Organization (WHO) estimates the incidence of PE to be seven times higher in developing countries (2.8% of live births) than in developed (0.4%).[ Severe PE/eclampsia is one of the most important causes of maternal mortality, associated with 50,000 to 100,000 annual deaths globally,[ as well as serious fetal and neonatal morbidity and mortality, especially in developing countries. This syndrome produces new-onset hypertension (>140/90 mm Hg) in the second half of pregnancy[ companied with either proteinuria (>300 mg/24 h), or multiorgan maternal dysfunction, especially kidney and liver failure, neurological complications, thrombocytopenia, or hemolysis.[ It is believed that PE results from defective spiral artery remodeling, which leads to an imbalance between anti and pro-angiogenic factors, favoring an anti-angiogenic environment, giving as a result, widespread endothelial dysfunction and organic failure.[ Serum samples have shown significantly increased soluble fms-like tyrosine kinase (sFlt-1) and decreased vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) concentrations in PE, compared to normotensive controls. In vitro studies showed that serum from PE inhibited tube formation in human umbilical vein endothelial cell (HUVEC) lines compared to that from controls, and administration of adenovirus expressing sFlt-1 to pregnant rats caused hypertension, albuminuria, and glomerular endotheliosis, similar to that observed in PE.[

1.1. The genetic component of PE

The complexity of PE suggests that some women are predisposed to suffering from PE. In this regard, there is evidence supporting that PE has an outsized familial risk, with a heritability factor of approximately 50% to 55%,[ of which 30% to 35% is attributed to maternal genotype, 20% fetal, 13% to a couple, and the rest to other effects.[ Family history of PE significantly increases woman’s risk of PE (24% and 163%).[ Besides, it has been proved that the familial form of PE is associated with a more severe phenotype.[ Predisposition to PE is multifactorial and probably polygenic. Candidate genes involved in different biological processes including inflammation, coagulation, vascular resistance, cell signaling pathways, and metabolic processes have been associated with PE due to their putative roles in its pathophysiology. Most of the early candidate gene studies have been focused on just nine genes: angiotensinogen (AGT), angiotensin I converting enzyme (ACE), angiotensin II receptor type 1 (AGTR1), angiotensin II receptor type 2 (AGTR2), coagulation factor II, thrombin (F2), coagulation factor V (F5), methylenetetrahydrofolate reductase (MTHFR), nitric oxide synthase 3 (NOS3) and tumor necrosis factor (TNF), which are involved in endothelial function and hemodynamics, immune response, lipid metabolism and oxidative stress, and thrombophilia.[ Attention has been also focused on increased sFlt-1 and decreased VEGF and PlGF were single nucleotide polymorphism (SNP) analyses have also shown association with PE. In this regard, genome-wide association studies (GWAS) have been performed in large cohorts of unrelated cases and controls to identify novel genetic loci through large-scale SNP analyses where the prevalence of specific SNPs is linked to phenotypes or disease.[ According to Brody et al.[, SNPs are variants in the genome occurring naturally in the human population, being the most frequent type of variation in the human genome, occurring once every several hundred base pairs throughout the genome.[ Each individual inherits one allele copy from each parent (the individual genotype at an SNP site is AA, BB, or AB).[ SNPs are defined as genomic locus where two or more alternative bases occur with appreciable frequency (0.1%).[ SNPs in genes can impact on messenger ribonucleic acid (mRNA) splicing, nucleo-cytoplasmic export, stability, and translation. When they are present within a coding sequence, lead to an amino acid change (referred to as a non-synonymous SNP or mutation), thus they can modify the protein’s activity.[ If the mutation is synonymous (does not change the nature of the amino acid), then translation rates or mRNA half-life may be affected. If the mutation causes a premature stop codon, this can lead to the production of a truncated protein product or a near-null phenotype due to nonsense mediated decay.[ For this, SNPs can be used as genetic markers to follow the inheritance patterns of chromosomal regions through generations and can be used in the study of genetic factors associated with human diseases.[ Different technologies have been used to detect SNPs such as restriction fragment length polymorphism (RFLPs), polymerase chain reaction (PCR) and genome shotgun sequencing, but they can be classically divided in technologies targeted SNP discovery (Denaturing gradient gel electrophoresis, chemical cleavage of mismatch, ribonuclease cleavage of mismatched deoxyribonucleic acid (DNA), single stranded conformation polymorphism, cleavage fragment length polymorphism analysis, MutS protein-binding assay, mismatch repair detection, T4 endonuclease VII cleavage of heteroduplex DNA, heteroduplex analysis, denaturing high performance liquid chromatography, uracil-DNA glycosylase (UNG)-mediated sequencing, ribonucleic acid (RNA) mediated finger printing with matrix-assisted laser desorption/ionization (MALDI) MS detection, sequencing by hybridization, direct DNA sequencing) and technologies for genotyping known SNPs (hybridization, primer extension, ligation, invasive cleavage, reaction formats, homogeneous reactions, reactions on solid support, detection mechanisms, luminescence detection, fluorescence detection, time- resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, electrical detection).[ Specifically, in PE, genetic predisposition is thought to be a significant etiological representative and SNPs in various genes were found to be associated with the risk of PE. In this regard, emerging evidence proposes that excessive maternal inflammatory response with cytokine-mediated endothelial damage may play a role in PE’s pathogenesis.[

1.2. Immunology of PE

Even though the main cause of the abnormal placentation remains unclear, genetic, environmental, and immunological factors have been associated.[ In this regard, it is believed that both, innate and adaptive immune processes are involved in the pathogenesis of PE, proposing that Th1 immunity is responsible for poor placentation and exacerbated inflammatory response and endothelial dysfunction seen in PE.[ This is relevant since T helper 1 (Th1) and T helper 2 (Th2) cytokine balance is important to maintain the success of normal pregnancy.[ In normal pregnancy, the production of Th1 cytokine is inhibited, and their overexpression predisposes to PE development.[ Moreover, fetal trophoblast acts as an alloantigen producing a systemic inflammatory response in the mother, but this is controlled and mild.[ Inflammatory response onset during the first twelve weeks could be given by interactions occurring between the decidual immune cells and trophoblast cells, then in the second and third trimester, a secondary inflammatory response could be due to syncytiotrophoblast microparticles that are released into the mother´s vascular system and are detectable in maternal circulation.[ Thus, two stages of the PE are proposed: poor trophoblastic invasion, given by altered production of immunoregulatory cytokines and angiogenic factors and a systemic, maternal-inflammatory response, primarily involving the endothelium, which is stimulated by the liberation of necrotic/apoptotic syncytiotrophoblast cells into the maternal circulation.[ This second stage of could be involved in poor fetal growth and can be linked with the development of intrauterine growth restriction.[ The pathophysiology of PE may involve several factors, including persistent placental hypoxia companied of the release of high amounts of syncytiotrophoblast microparticle. Besides, damage-associated molecular pattern molecules released during hypoxia and syncytiotrophoblast microparticle, which bind Toll-like receptors (TLRs), may activate monocytes, dendritic cells (DCs), natural killer (NK) cells, and neutrophils, enhancing persistent inflammatory conditions.[ The development of hypertension in preeclamptic women from an immunological point of view is also related with endothelial dysfunction induced by neutrophil activation and neutrophil extracellular trap formation. Moreover, preeclamptic women have higher levels of nonclassic and intermediate monocytes and lower levels of positive lymphoid blood DC antigen 2 DCs.[ In this regard, the inflammatory process may be due to the cytokines secreted by these cells and to changes in adaptive-immunesystem cells, which are also modulated in PE. The changes in T cell subsets that may be seen in PE include low regulatory T cells (Treg) activity, a shift toward Th1 responses, and the presence of T helper 17 (Th17) lymphocytes. B lymphocytes (B cells) can participate in the pathophysiology of PE by producing autoantibodies against adrenoreceptors and autoantibodies that bind the angiotensin-1 receptor.[ It is believed that both, innate and adaptive immune processes are involved in the pathogenesis of PE, proposing that Th1 immunity is responsible for poor placentation and exacerbated inflammatory response and endothelial dysfunction seen in PE.[ This is relevant since Th1/Th2 cytokine balance is important to maintain the success of normal pregnancy.[ In normal pregnancy, the production of Th1 cytokine is inhibited, and their overexpression predisposes to PE development.[ There are also reports showing excessive innate immune activity and a change toward an inflammatory cytokine profile in PE.[ For instance, preeclamptic patients show high levels of Th1 cytokines, tumor necrosis factor-alpha (TNF-α) and interferon-gamma cytokine (IFN-γ) and low interleukin 4 (IL-4) production by phytohemagglutinin-stimulated peripheral blood mononuclear cells. Besides, their placentas show suppression of interleukin 10 (IL-10) and transforming growth factor beta receptor 1 (TGF-β1) and altered interleukin 2 (IL-2) IL-2/IL-10 and TNF-α/IL-10 ratios.[ PE is also associated with increased numbers of Th17 cells that secrete interleukin 17 (IL-17) and interleukin 22 (IL-22) and play critical roles in disease development.[ Given that IL-22 shares 22% sequence identity with IL-10, and IL-22 is overexpressed in the preeclamptic mother and neonate cord blood exposed to PE, it is thought that IL-22 may be an important inflammatory biomarker of PE.[ From a clinical perspective, proinflammatory cytokines, have been studied to find a panel of markers for diagnosing PE. In this regard, a systematic review showed that interleukin 6 (IL-6), interleukin 8 (IL-8), TNFα, and C-reactive protein (CRP) could be useful to identify pregnant women at risk of developing PE, particularly in the second and third trimesters.[ Nevertheless, there is not a single inflammatory marker for routine clinical use to predict/ identify PE onset or progression.[ Even though increased sFlt-1 and decreased VEGF and PlGF (and their SNPs) have been related with early onset of PE (Fig. 1), they are not used commonly as clinical markers. As a single cytokine is not reliable markers for early identification of PE, a combination of markers in conjunction with identification of clinical risk factors is mandatory.[ Therefore, a broad examination of factors affecting inflammatory markers in PE could help to predict/identify PE. Given that SNPs in genes can impact on mRNA splicing, nucleo-cytoplasmic export, stability, and translation, they must be studied. This review aims to compile the most recent information regarding SNPs in Th1, Th2 and Th17 cytokines and their association with PE.
Figure 1.

(A) VEGF, PIGF, and TGF-β are required to maintain endothelial function in placenta. During normal pregnancy, endothelial homeostasis is maintained by signaling of theses growth factors. (B) In PE, the secretion of sFlt1 and sEng (antiangiogenic regulators) inhibits VEGF, PIGF, and TGF-β signaling resulting in endothelial cell dysfunction. Besides, SNPs presence in VEGF and PIGF can also alter their function, and have been associated with PE.[ FIt-1 = soluble fms-like tyrosine kinase, PE = preeclampsia, SNP = single nucleotide polymorphism, TGF-β1 = transforming growth factor beta receptor 1, PIGF = phosphatidylinositol glycan anchor biosynthesis class F, VEGF = vascular endothelial growth factor.

(A) VEGF, PIGF, and TGF-β are required to maintain endothelial function in placenta. During normal pregnancy, endothelial homeostasis is maintained by signaling of theses growth factors. (B) In PE, the secretion of sFlt1 and sEng (antiangiogenic regulators) inhibits VEGF, PIGF, and TGF-β signaling resulting in endothelial cell dysfunction. Besides, SNPs presence in VEGF and PIGF can also alter their function, and have been associated with PE.[ FIt-1 = soluble fms-like tyrosine kinase, PE = preeclampsia, SNP = single nucleotide polymorphism, TGF-β1 = transforming growth factor beta receptor 1, PIGF = phosphatidylinositol glycan anchor biosynthesis class F, VEGF = vascular endothelial growth factor.

2. Methods

A systematic search was performed on PubMed, National Center for Biotechnology Information, Web of Sciences, Google scholar, Cochrane library and Embase from 2010 to July 2022 to articles matching the following criteria: “single-nucleotide polymorphisms,” “SNP,” “polymorphisms,” “IFN-γ,” “IFN gamma,” “TNF-alpha,” “TNF-α,” “IL-4,” “IL-6,” “IL-10,” “IL-17A,” “IL-22,” and “PE,” and their combinations in lowercase letters. The Boolean operators “OR” and “AND” were used, and the strategy was carried out both individually and jointly. The titles and abstracts were screened and acquired relevant full-text manuscripts for further analysis. No ethics committee or institutional review board needed to revise the study.

2.1. Cytokine-polymorphisms associated with PE

For a long time, single-nucleotide polymorphisms (SNPs) in cytokine have been associated with certain inflammatory diseases and obstetric complications.[ Nevertheless, factors such as selection criteria, ethnic groups, and linkage disequilibrium patterns can lead to differences in results. Besides every pathophysiologic feature could have different clinical patterns. Several studies have investigated SNPs in inflammatory mediator genes and risk of PE; however, the results between studies showed inconsistencies (Franchim et al[; Ghasemi et al[; Andraweera et al[; Li et al[; Goddard et al[). This could be possible due to variations in the ethnic groups and heterogeneity of PE included in different studies. Additionally, controversial results reported by different investigators may in part be because of selection criteria. Genotype frequencies of SNPs and linkage disequilibrium patterns can differ among ethnic groups, leading to different results.[ Moreover, distinct clinical patterns may involve different pathological mechanisms.[

2.2. Th1 cytokines

2.2.1. IFN-γ.

The interferon-gamma cytokine (IFN-γ) is encoded by the IFNG gene, also known as IFG and IFI. It is localized on chromosomal region 12q15[ and encodes a soluble cytokine, a member of the type II interferon class. The protein is secreted by cells of the innate and adaptive immune responses. The main functions of IFN-γ are activation of macrophages for destroying phagocytosed microorganism, stimulation, and differentiation of naive LT CD4 + into subpopulation Th1 by inhibiting differentiation into Th2 phenotype, stimulation of the expression of major histocompatibility complex class 1 (MHC-I) and class 2 (MHC-II), and finally, co-stimulate antigen-presenting cells.[ Moreover, IFN-γ has been associated with increased susceptibility to viral, bacterial, and parasitic infections, and it has been also related to leukemia and several autoimmune diseases.[ High levels of IFN-γ and other cytokines such as interleukin 1 (IL-1), IL-2, IL-8, and tumor necrosis factor-alpha (TNF-α) are associated with pregnancy complications such as preterm labor and intrauterine growth retardation.[ In this regard, IFN-γ as well as IL-2 and TNF-α, induce trophoblastic apoptosis, restrained trophoblast differentiation that produces an incomplete trophoblastic invasion of spiral arteries, and impaired placental implantation, leading to PE.[ There is only a +874A/T SNP associated with PE, in which T/T genotype in that position is related to high levels of IFN-γ production and has been associated with an increased risk of severe PE in the Brazilian population (Table 1).[ On the other hand, the same SNP was investigated in the Brazilian and Iranian populations, were no found association (Table 2).
Table 1

Cytokine-SNPs associated with preeclampsia.

AuthorsPopulation studiedPopulation sizeMethodologySNPFinding
IFN-γ
 Pinheiro et al[48]BrazilianSPE: 116Ctl: 107NP: 58PCR-SSPrs2430561+874T/T genotype seems to plays a role in PE occurrence
TNF-α
 Tavakkol Afshari et al*IranianPE: 153Ctl: 150PCR-RFLPrs1800629rs361525Significant association between TNF-alpha G-308A and G-238A genotype and PE
 Mohajertehran et al[64]IranianPE: 54Ctl: 50PCR-RFLPrs1800629Significant association between SNP of promoter region of TNF-alpha G-308A with PE
 Mirahmadian et al[65]IranianPE: 160Ctl: 100ASO-PCRrs1800629rs361525Both, -308A and -238G allele were associated with risk of PE
 Molvarec et al[66]HungarianPE: 140Hellp: 69Ctl: 144PCR-RFLPrs1800629SNP G-308A was associated with risk of complicated PE with severe IUGR
 Pazarbasi et al[67]TurkishE: 40PE: 113NP: 80PCR-RFLPrs1800629rs1799724Both SNPs were associated with the PE susceptibility
 Saarela et al[68]FinnishPE: 133Ctl: 115PCR-RFLPrs1799724rs1800629Both SNPs showed a significant haplotype association with susceptibility to PE
 Harmon et alAmericanPE: 1598Ctl: 918Illumina GoldenGate Plataformrs1800629Association was for PE among European Americans
 Naderi, et alIranianPE: 153Ctl: 140PCR-RFLPrs361525The AA genotype and the A allele may carry an increased risk for PE
 Puppala et al[10]IndianPE: 100Ctl: 100PCR-RFLPrs1800629SNP -308G/A was associated with risk of PE
 Zubor et al[69]SlovakPE: 38Ctl: 38PCR-RFLPrs1800629-308A allele was associated with risk of PE
IL-4
 Fraser et al[70]EnglandPE: 117Ctl: 146PCR-RFLPrs2243250-590T/T homozygous were associated in risk of PE
 Salimi et al[71]IranianPE: 192Ctl: 186PCRrs79071878VNTR polymorphism of IL-4 gene has significantly increased the risk of PE
IL-6
 Puppala et al[72]IndianPE: 100Ctl: 100PCR-RFLPrs1800795SNP -174G/C was associated with risk of PE
IL-10
 Fan et al[30]ChinesePE: 142Ctl: 260PCR-RFLPrs1800872CC genotype of -592A/C was observed to be associated with PE
 Liu et al[73]ChinesePE: 177Ctl: 182PCR-RFLPrs1800871CC genotype of -819T/C was associated with risk of PE.
 Song and Zhong[74]ChinesePE: 177Ctl: 182PCR-RFLPrs1800872-592A/C was associated with an increased risk of early-onset PE
 Sowmya et a[75]IndianPE: 120Ctl: 120ARMS-PCRrs1800872rs1800871-819C allele and - 592A allele were associated with PE
 Sowmya et al§IndianPE: 120Ctl: 120ARMS-PCRrs1800871Significant association of C allele of IL-10 -819 promoter polymorphism with PE
 Vural et al[76]TurkishPE: 101NP: 95ASO-PCRrs1800896AA genotype has 3.38-fold-increased risk of developing PE
 Mirahmadian et al[65]IranianPE: 160Ctl: 100ASO-PCRrs1800871rs1800872-819C/C and -592C/C were associated with risk of PE
 Kamali-Sarvestani et al[77]IranianPE: 134Ctl: 164ASO-PCRrs1800896-1082G allele in PE may be considered as a genetic susceptibility to development of PE
 Daher et al[78]BrazilianPE: 151Ctl: 189PCR-SSPrs1800896SNP of IL-10 -1082 is associated with PE
 Zhou et alChinesePE: 117Ctl: 286Multiplex PCRrs1800896A-1082G allele frequency was significantly higher in PE
 Elhawary et al[79]EgyptianPE: 20Ctl: 20PCR-RFLPrs1800896Significant difference between the frequency of genotype in GG, AA and A and G allele and development of PE
 Raguema et alTunisianPE: 345Ctl: 300RT-PCRrs1800871-819T/T variant and the ATA haplotype represent genetic risk for PE
IL–17A
 Lang et al[80]ChinesePE: 120Ctl: 120NP: 150PCR-RFLPrs2275913Heterozygous (GA) and minorallele (A) were significantly more prevalent in PE women
IL-22
 Niu et al[81]ChinesePE: 107Ctl: 1263RT-PCRrs2227485A significant difference under the recessive model of the T allele (TT/CC + CT genotype)

Ctl = control (normotensive pregnancy), E = Eclampsia, GH = gestational hypertension, NP = Non-pregnant women, PE = preeclampsia, SNP = single nucleotide polymorphism, SPE = Severe preeclampsia.

Tavakkol Afshari Z, Rahimi HR, Ehteshamfar SM, et al. Tumor necrosis factor-alpha and nterleukin-1-beta polymorphisms in pre-eclampsia. Iranian J Immunol. 2016;13:309–16.

Harmon QE, Engel SM, Wu MC, et al. Polymorphisms in inflammatory genes are associated with term small for gestational age and preeclampsia. Am J Reprod Immunol. 2014;71:472–84.

Naderi M, Yaghootkar H, Tara F, et al. Tumor necrosis factor-alpha polymorphism at position -238 in preeclampsia. Iran Red Crescent Med J. 2014;16:e11195.

Sowmya S, Ramaiah A, Sunitha T, et al. Role of IL-10 -819(T/C) promoter polymorphism in preeclampsia. Inflammation. 2014;37:1022–7.

Zhou L, Cheng L, He Y, et al. Association of gene polymorphisms of FV, FII, MTHFR, SERPINE1, CTLA4, IL10, and TNFalpha with pre-eclampsia in Chinese women. Inflamm Res. 2016;65:717–24.

Raguema N, Gannoun MBA, Zitouni H, et al. Interleukin-10 rs1800871 (-819C/T) and ATA haplotype are associated with preeclampsia in a Tunisian population. Pregnancy Hypertens. 2018;11:105–10.

2.2.2. TNF-alpha.

The tumor necrosis factor-alpha cytokine (TNF-α) is encoded by the TNF gene, also known as DIF, TNFSF2, and TNLG1F. It is located in the human leukocyte antigen (HLA) class II region of the major histocompatibility complex (MHC) on chromosomal region 6p21.33.[ TNF-α is multifunctional proinflammatory Th1 cytokine, mainly secreted by macrophages, recognized for its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR.[ TNF-alpha is involved in the regulation of a variety of biological processes such as cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation.[ Moreover, this cytokine has been implicated in a variety of diseases, including autoimmune diseases, Alzheimer, and cancer.[ During pregnancy, TNF-α has been involved with PE etiology. In this regard, increased plasma levels of TNF-α in trophoblastic cells of the placenta have been found in preeclamptic patients while IL-10 and IL-4 levels are decreased.[ This cytokine imbalance leads to chronic peripheral and placental inflammation.[ In addition, there is evidence pointing to some SNPs that act as transcriptional regulators of this cytokine in the promoter region (-308G/A, -238G/A) (Table 1),[ such as the G/A polymorphism at position -308 that has been associated with an increased risk of PE.[ Additionally, preeclamptic women are significantly more likely to carry the upregulating TNF-a -308 A/G than normotensive women.[ Besides, the allele frequency (AA) in -308 position is significantly higher among preeclamptic Slovak, Finnish, Iranian and the Turkish population[ and eclamptic Turkish women.[ Interestingly, the AA allele frequency has been found significantly higher among preeclamptic patients with intrauterine growth restriction (IUGR) compared to those without IUGR in Hungary population.[ Cytokine-SNPs associated with preeclampsia. Ctl = control (normotensive pregnancy), E = Eclampsia, GH = gestational hypertension, NP = Non-pregnant women, PE = preeclampsia, SNP = single nucleotide polymorphism, SPE = Severe preeclampsia. Tavakkol Afshari Z, Rahimi HR, Ehteshamfar SM, et al. Tumor necrosis factor-alpha and nterleukin-1-beta polymorphisms in pre-eclampsia. Iranian J Immunol. 2016;13:309–16. Harmon QE, Engel SM, Wu MC, et al. Polymorphisms in inflammatory genes are associated with term small for gestational age and preeclampsia. Am J Reprod Immunol. 2014;71:472–84. Naderi M, Yaghootkar H, Tara F, et al. Tumor necrosis factor-alpha polymorphism at position -238 in preeclampsia. Iran Red Crescent Med J. 2014;16:e11195. Sowmya S, Ramaiah A, Sunitha T, et al. Role of IL-10 -819(T/C) promoter polymorphism in preeclampsia. Inflammation. 2014;37:1022–7. Zhou L, Cheng L, He Y, et al. Association of gene polymorphisms of FV, FII, MTHFR, SERPINE1, CTLA4, IL10, and TNFalpha with pre-eclampsia in Chinese women. Inflamm Res. 2016;65:717–24. Raguema N, Gannoun MBA, Zitouni H, et al. Interleukin-10 rs1800871 (-819C/T) and ATA haplotype are associated with preeclampsia in a Tunisian population. Pregnancy Hypertens. 2018;11:105–10. Regarding G/A polymorphism at position -238, the allele G distribution is significantly higher in the PE group, moreover, is related to high levels of TNF-α production compared with the control group 136. Furthermore, the haplotype C/A, of two polymorphisms, -850C/T and -308G/A, have been associated with an increased risk of PE in the Finnish population.[ On the other hand, the same SNPs were investigated in the Brazilian, American, Austrian, Scottish, Italian, Finnish, and Turkish populations, where no found any association with the risk of PE (Table 2).
Table 2

Cytokine-SNPs not associated with preeclampsia.

AuthorsPopulation studiedPopulation sizeMethodologySNPFinding
IFN-γ
 Daher et al[78]BrazilianPE: 151Ctl: 189PCPCR-SSPrs2430561No association in 874A/T SNP and PE was observed
 Kamali-Sarvestani et al[77]IranianPE: 134Ctl: 164ASO-PCRrs2430561No association between 874A/T polymorphism and PE was observed
 de Lima et al[56]BrazilianPE: 92E: 73Ctl: 101PCR-SSPrs2430561SNP of 874A/T was not association with PE women
TNF-α
 Daher et al[78]BrazilianPE: 151Ctl: 189PCR-SSPrs1800629SNP of -308G/A was no associated with PE
 Pinheiro et al[48]BrazilianSPE: 116Ctl: 107NP: 58PCR-SSPrs1800629SNP of -308G/A was no associated with PE
 Livingston et al*AmericanSPE: 112Ctl: 106PCR-RFLPrs1800629Neither genotypic frequency and mutant alleles were associated with severe PE
 Stonek et al[6]AustrianPE: 107Ctl: 107Multiplex PCRrs1800629SNP in G-308A was no associated with PE
 Haggerty et al[82]AmericanPE: 150Ctl: 661TaqManrs1800629-308 G/A was no associated with PE
 de Lima et al[56]BrazilianPE: 92E: 73Ctl: 101PCR-SSPrs1800629SNP of -308G/A was no associated with PE
 Freeman et al[]ScottishPE: 106Ctl: 212PCR-RFLPrs1800629No association between -308G/A and the risk of PE
 Previtera and Restaino[9]ItalianSPE: 20Ctl: 10Sanger sequencingrs1800629No association was observed in -308G/A
 Heiskanen et alFinnishPE: 133Ctl: 115PCR-RFLPrs1799724No association was observed in C-850T and risk of PE
 Vural et al[76]TurkishPE: 101NP: 95PCR-RFLPrs1800629No significant differences was found in genotype or allele frequencies in -308G/A
IL-6
 Pinheiro et al[48]BrazilianSPE: 116Ctl: 107NP: 58PCR-SSPrs1800795No association between -174G/C polymorphisms and PE was observed
 Andraweera et al[51]Sri LankaPE: 175Ctl: 171SequenomMass ARRAY systemrs1800795No significant differences was found in-174G/C and PE risk
 Freeman et al[]ScottishPE: 106Ctl: 212PCR-RFLPrs1800795No association between -174G/C and the risk of PE
 Vural et al[76]TurkishPE: 101NP: 95PCR-RFLPrs1800795No significant differences was found in genotype or allele frequencies in -174G/C
 Saarela et al[]FinnishPE: 133Ctl: 115PCR-RFLPrs1800795No significant difference was found in -17G/C and PE risk
 Fanet al[30]ChinesePE: 142Ctl: 260PCR-RFLPrs1800795rs1800796rs1800797No significant differences were found in genotype or allele frequencies in -174G/C, -597G/A and -572 G/C
 Harmon et al[#]AmericanPE: 1598Ctl: 918Illumina GoldenGate Plataformrs1800795There was no association between IL-6 SNP and the risk of PE
 Daher et al[78]BrazilianPE: 151Ctl: 189PCR-SSPrs1800795SNP of IL-6 -174G/C was no associated with PE
 Bayoumy et al**SaudiGH: 60PE: 49Ctl: 100PCR Allele Discriminationrs1800795No association was observed in-174G/C and risk of PE
 Stonek et al††AustrianPE: 14Ctl: 1367ASO-PCRrs1800795-174 G/C is not a genetic marker for risk of PE
 de Lima et al[56]BrazilianPE: 92E: 73Ctl: 101PCR-SSPrs1800795No significant difference was found in SNP of -174G/C and PE risk
 Valencia Villalvazo et al‡‡MexicanPE: 411Ctl: 613RT-PCRrs1800795SNP of IL-6 -174G/C was no association with PE women
 Stonek et alAustrianPE: 107Ctl: 107Multiplex PCRrs1800795IL-6 G174C was no associated with PE
IL-10
 Kamali-Sarvestani et al[77]IranianPE: 134Ctl: 164PCR-RFLPrs1800871rs1800872No association between -819T/C, -592A/C polymorphisms and PE was observed
 Previtera and Restaino§ItalianSPE: 20Ctl: 10Sanger sequencingrs1800872No association was observed in -592A/C
 Pinheiro et al[48]BrazilianSPE: 116Ctl: 107NP: 58PCR-SSPrs1800896No association in -1082G/A SNP and PE was observed
 Sowmya et al§§IndianPE: 88Ctl: 100ARMS-PCRrs1800896No association was observed in -1082G/A and risk of PE
 de Lima et al[56]BrazilianPE: 92E: 73Ctl: 101PCR-SSPrs1800871rs1800896rs1800872No association between -819T/C, -1082G/A and - 592A/C polymorphisms and PE was observed
 Valencia Villalvazo et al‡‡MexicanPE: 411Ctl: 613RT-PCRrs1800896SNP in -1082G/A was no association with PE women
 Stonek et alAustrianPE: 107Ctl: 107Multiplex PCRrs1800896IL-10 G-1082A was no associated with PE
 Haggerty et al[82]AmericanPE: 150Ctl: 661TaqManrs1800871rs1800896There were no differences in -819C/T and -1082G/A allele distribution
IL-17A
 Lang et al[80]ChinesePE: 120Ctl: 120NP: 150PCR-RFLPrs1974226rs3748067No significant genetic association were observed in the distribution *1245C/T and 1249C/T and risk of PE
 Wang et al‖‖ChinesePE: 1031Ctl: 1.298RT- PCR Allele Discriminationrs2275913-197A/G was no associated with risk of PE
 Anvari et al[83]IranianPE: 261Ctl: 278PCR-RFLPrs2275913No significant differences in genotypic and allelic frequencies was found in -197A/G

Ctl = control (normotensive pregnancy), E = Eclampsia, GH = gestational hypertension, NP = Non-pregnant women, PE = preeclampsia, SNP = single nucleotide polymorphism, SPE = Severe preeclampsia.

Livingston JC, Park V, Barton JR, et al. Lack of association of severe preeclampsia with maternal and fetal mutant alleles for tumor necrosis factor alpha and lymphotoxin alpha genes and plasma tumor necrosis factor alpha levels. Am J Obstet Gynecol. 2001;184:1273–7.

Stonek F, Hafner E, Metzenbauer M, et al. Absence of an association of tumor necrosis factor (TNF)-alpha G308A, interleukin-6 (IL-6) G174C and interleukin-10 (IL-10) G1082A polymorphism in women with preeclampsia. J Reprod Immunol. 2008;77:85–90.

Freeman DJ, McManus F, Brown EA, et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension (Dallas, Tex: 1979). 2004;44:708–14.

Previtera F, Restaino S. Gene polymorphism in five target genes of immunosuppressive therapy and risk of development of preeclampsia.Healthcare (Basel). 2021;9:821.

Heiskanen J, Romppanen EL , Hiltunen M, et al. Polymorphism in the tumor necrosis factor-alpha gene in women with preeclampsia. J Assist Reprod Genet. 2002;19:220–3.

Saarela T, Hiltunen M, Helisalmi S, et al. Polymorphisms of interleukin-6 , hepatic lipase and calpain-10 genes, and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2006;128:175–9.

Harmon QE, Engel SM, Wu MC, et al. Polymorphisms in inflammatory genes are associated with term small for gestational age and preeclampsia. Am J Reprod Immunol. 2014;71:472–84.

Bayoumy NM, Al-Sharaidh AS, Babay ZH, et al. The role of interleukin-6 promoter polymorphism -174G/C in Saudi women with hypertensive disorders of pregnancy. Saudi Med J. 2013;34:689–94.

Stonek F, Metzenbauer M, Hafner E, et al. Interleukin 6 -174 G/C promoter polymorphism and pregnancy complications: results of a prospective cohort study in 1626 pregnant women. Am J Reprod Immunol. 2008;59:347–51.

Valencia Villalvazo EY, Canto-Cetina T, Romero Arauz JF, et al. Analysis of polymorphisms in interleukin-10, interleukin-6, and interleukin-1 receptor antagonist in Mexican-Mestizo women with pre-eclampsia. Genet Test Mol Biomarkers. 2012;16:1263–9.

Sowmya S, Ramaiah A, Sunitha T, et al. Evaluation of interleukin-10 (G-1082A) promoter polymorphism in preeclampsia. J Reprod Infertil. 2013;14:62–6.

Wang H, Guo M, Liu F, et al. Role of IL-17 variants in preeclampsia in Chinese Han Women. PloS One. 2015;10:e0140118.

Cytokine-SNPs not associated with preeclampsia. Ctl = control (normotensive pregnancy), E = Eclampsia, GH = gestational hypertension, NP = Non-pregnant women, PE = preeclampsia, SNP = single nucleotide polymorphism, SPE = Severe preeclampsia. Livingston JC, Park V, Barton JR, et al. Lack of association of severe preeclampsia with maternal and fetal mutant alleles for tumor necrosis factor alpha and lymphotoxin alpha genes and plasma tumor necrosis factor alpha levels. Am J Obstet Gynecol. 2001;184:1273–7. Stonek F, Hafner E, Metzenbauer M, et al. Absence of an association of tumor necrosis factor (TNF)-alpha G308A, interleukin-6 (IL-6) G174C and interleukin-10 (IL-10) G1082A polymorphism in women with preeclampsia. J Reprod Immunol. 2008;77:85–90. Freeman DJ, McManus F, Brown EA, et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension (Dallas, Tex: 1979). 2004;44:708–14. Previtera F, Restaino S. Gene polymorphism in five target genes of immunosuppressive therapy and risk of development of preeclampsia.Healthcare (Basel). 2021;9:821. Heiskanen J, Romppanen EL , Hiltunen M, et al. Polymorphism in the tumor necrosis factor-alpha gene in women with preeclampsia. J Assist Reprod Genet. 2002;19:220–3. Saarela T, Hiltunen M, Helisalmi S, et al. Polymorphisms of interleukin-6 , hepatic lipase and calpain-10 genes, and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2006;128:175–9. Harmon QE, Engel SM, Wu MC, et al. Polymorphisms in inflammatory genes are associated with term small for gestational age and preeclampsia. Am J Reprod Immunol. 2014;71:472–84. Bayoumy NM, Al-Sharaidh AS, Babay ZH, et al. The role of interleukin-6 promoter polymorphism -174G/C in Saudi women with hypertensive disorders of pregnancy. Saudi Med J. 2013;34:689–94. Stonek F, Metzenbauer M, Hafner E, et al. Interleukin 6 -174 G/C promoter polymorphism and pregnancy complications: results of a prospective cohort study in 1626 pregnant women. Am J Reprod Immunol. 2008;59:347–51. Valencia Villalvazo EY, Canto-Cetina T, Romero Arauz JF, et al. Analysis of polymorphisms in interleukin-10, interleukin-6, and interleukin-1 receptor antagonist in Mexican-Mestizo women with pre-eclampsia. Genet Test Mol Biomarkers. 2012;16:1263–9. Sowmya S, Ramaiah A, Sunitha T, et al. Evaluation of interleukin-10 (G-1082A) promoter polymorphism in preeclampsia. J Reprod Infertil. 2013;14:62–6. Wang H, Guo M, Liu F, et al. Role of IL-17 variants in preeclampsia in Chinese Han Women. PloS One. 2015;10:e0140118.

2.3. Th2 cytokines

2.3.1. IL-4.

The interleukin 4 cytokine (IL-4) is translated by the IL4 gene, also known as BSF1; IL-4; BCGF1; BSF-1; BCGF-1 and IL4 is localized on chromosomal region 5q31.1.[ IL-4 protein encodes a pleiotropic cytokine Th2 produced by activated T cells. In this regard, IL-4 is considered an important cytokine for tissue repair, counteracting the effects of proinflammatory Th1 cytokines, however, it also promotes allergic airway inflammation.[ Moreover, IL-4 regulates a variety of human host responses such as allergic, anti-parasitic, wound healing, and acute inflammation.[ This protein has been reported to promote the resolution of neutrophil-mediated acute lung injury. In an allergic response, IL-4 plays a key role in the production of immunoglobulin E (Ig E).[ IL-4 cytokine is implicated in a wide variety of disease as chronic asthma, gastric cancer, breast cancer, leukemia, oral carcinoma, bladder carcinoma, colonic cancer, chronic periodontitis, and inflammatory dilated cardiomyopathy.[ In pregnancy the Th2 cytokines, such as IL-4, play an important role in the regulation and control of inflammation, leading to the normal development of gestation. In this regard, the production of IL-4 is enhanced at the feto-maternal interface during pregnancy, this production has been observed depressed in pregnant that suffering from recurring spontaneous abortions.[ In rats, IL-4 has proved that decrease the inflammation and ultimately, improve hypertension in response to placental ischemia.[ On the other hand, the -590C/T SNP in IL-4 has been associated with PE, in T/T genotype in that position has been associated with marked trend of PE in UK population.[ Moreover, another SNP, the variable number tandem repeat (VNTR) RP2 allele has been associated with PE susceptibility in Iranian pregnant.[

2.3.2. IL-6.

The interleukin 6 cytokine (IL-6) is translated by the IL6 gene, also known as CDF; HGF; HSF; BSF2; IL-6; BSF-2; IFNB2; IFN-beta-2 and IL6 is localized on chromosomal region 7p15.3.[ IL-6 protein encodes a proinflammatory cytokine is primarily produced by activated cells at sites of acute and chronic inflammation. This cytokine is a soluble mediator with pleiotropic effects on inflammation and the maturation of B cells.[ Additionally, has been observed to be an endogenous pyrogen capable of inducing fever in patients with autoimmune diseases or infections.[ The IL-6 cytokine is implicated in a wide variety of inflammatory disease, for instance, juvenile rheumatoid arthritis, rheumatoid arthritis or susceptibility to diabetes mellitus.[ There are two faces of IL-6 on Th1/Th2 differentiation.[ IL-6 promotes Th2 differentiation and at the same time inhibits Th1 polarization through two independent molecular mechanisms: IL-6 activates transcription mediated by nuclear factor of activated T cells (NFAT) leading to production of IL-4 by naive CD4+ T cells and their differentiation into effector Th2 cells. The inhibition of Th1 differentiation by IL-6 is IL-4- and NFAT-independent. IL-6 inhibits Th1 differentiation by upregulating suppressor of cytokine signaling (SOCS)-1 expression interfering with IFN-γ signaling and the development of Th1 cells. Thus, by using two independent molecular mechanisms, IL-6 plays a dual role in Th1/Th2 differentiation.[ IL-6 is a cytokine highly expressed in the feminine tract reproductive and gestational tissues and has a differential effect during pregnancy how in the development the placenta and the requirements of immunological adaptation on the fetus tolerances, in this regard IL-6 plays an important function on the pathophysiology of infertility and gestational disorders.[ Preterm labor has been associated with elevated levels of maternal serum IL-6 cytokine, whereas it is observed that serum IL-6 levels increase with preeclamptic women and decreased production of IL-6 in placental tissue,[ in this regard, IL-6 is not essential for the success of the pregnancy, however, it is important in modulation during the implantation of the embryo.[ Regarding SNPs, in IL-6, the -174G/C genotype has been associated with the risk of PE in the Indian population.[ But these results differ from other investigations, where a lot of groups have evaluated this SNP in Brazilian, American, Sri Lanka, Saudi, Austrian, Scottish, Turkish, Finnish, Chinese and Mexican populations and them no found any association with the risk of PE (Table 2).

2.3.3. IL-10.

The interleukin 10 cytokine (IL-10) is encoded by the IL10 gene, also known as CSIF, TGIF, GVHDS and IL10A. It is located on the chromosomal region 1q32.1.[ The IL-10 is produced primarily by monocytes and to a lesser extent by lymphocytes. It has two principal roles, immunoregulation and inflammation. Additionally, IL-10 produces downregulation of Th1 cytokines expression, MHC class II, and co-stimulatory molecules on macrophages.[ It also helps with B cell survival, proliferation, and antibody production.[ IL-10 cytokine has been implicated in a wide variety of disease as pancreatitis, diabetic nephropathy, asthma susceptibility, ischemic stroke, and coronary artery disease.[ In normal pregnancy, IL-10 has three major beneficial roles since this cytokine plays a key role in Th2 response: promoting successful placentation, controlling inflammation, and regulating vascular function.[ In this regard, levels of serum IL-10 are increased during a normal pregnancy and remain high until delivery. Besides, in normal human placental tissue, it has been observed higher levels of IL-10 during first and second trimesters compared to the third trimester of pregnancy, which means that provides an important balance for inflammation at the fetal-maternal interface.[ Interestingly, some SNPs in the proximal (-1082A/G, -819T/C and -592A/C) and distal regions of the promoter region of the IL-10 gene[ are transcriptional regulators (Table 1).[ For instance, the A/G polymorphism at position -1082 is related to lower IL-10 production.[ It has been associated with an increased risk of PE in Turkish, Brazilian, and Egyptian populations.[ The T/C polymorphism at position - 819 found an increased distribution of the normal allele in patients[ and was associated with increased risk of PE in Chinese[ population, and with early-onset PE in an Indian population[ were specifically diplotypes of IL-10: -1082A with -819C; -1082G with -819C; -819C with -592C; -1082A with -592C; and -1082G with -592C were associated. Several studies have shown that A/C polymorphism at position -592 is associated with low levels of IL-10 production.[ Its presence has been correlated with an elevated risk of developing PE in Iranian population[ and the CC and AC + CC genotypes of IL-10 -592A/C are also associated with high risk when compared to the AA genotype in Chinese population.[ Besides, this SNP has been related to early-onset PE in Indian[ and Chinese[ populations. On the other hand, these three SNPs in IL-10 have been widely studied in different populations as Iranian, Brazilian, American, Italian, Indian, Mexican, and Austrian not having found any association with risk of PE (Table 2).

2.4. Th17 cytokines

2.4.1. IL-17A.

The interleukin 17A cytokine (IL-17A) is translated by IL17A gene, also known as IL17; CTLA8; IL-17; CTLA-8; IL-17A and IL17A is localized on chromosomal region 6p12.2,[ and this gene encoded a proinflammatory cytokine produced by activated T cells and by other cell subsets, such as γδT cells, cytotoxic CD8+ T cells, innate tissue-specific cells, innate lymphoid cells (ILCs), and myeloid cells.[ This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. The IL-17A can stimulate the expression of IL-6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). The IL-17A cytokine has been implicated in several chronic inflammatory diseases like rheumatoid arthritis, psoriasis, multiple sclerosis, and autoimmune diseases.[ The IL-17 family has six members IL-17A (IL17), IL-17B, IL-17C, IL-17D, IL-17E (IL-25), and IL-17F. In fact, IL-17A and IL-17F are the most closely related, are coexpressed in linked genes and usually are coproduced by Th17 cells.[ The IL-17A promotes hypertension, because is traditional cardiovascular risk factor that contributes to myocardial infarction and stroke.[ The Th17 cells participate in pregnancy related pathologies, including recurrent spontaneous abortion and PE, and imbalances between Th1/Treg/Th17 subsets in blood circulation and uterus have been reported.[ In humans, it has been suggested that IL-17 can increase in the invasive capacity of JEG-3 cells (trophoblast-like human choriocarcinoma cell line) and increase progesterone secretion significantly.[ In normal pregnancy, the size of peripheral blood TH17 cells decrease, but in PE cases, this change is not observed, being higher in the peripheral blood and decidua.[ Only one SNP has been reported affecting the expression of IL-17, causing recurrent pregnancy loss.[ There is an association between the heterozygous GA and the minor allele A at position -197 and PE in Chinese women, and is related to high levels of IL-17A production compared with the control group.[ However, another studies did not found association with PE in Chinese and Iranian population (Table 2).

2.4.2. IL-22

Interleukin-22 cytokine (IL-22) is a member of the IL-10 family (along with IL-10, IL-19, IL-20, IL-24, IL-26, IL-28, and IL-29). IL-22 is key for the host defense against extracellular pathogens at mucosal surfaces strengthening epithelial barrier functions and is involved in tissue homeostasis, tissue repair and wound healing.[ Although IL-22 is classified a Th17 cytokine, since is mostly coexpressed with IL-17 can be produced by a wide variety of cells from adaptive and the innate immune system: CD4+ T cells (Th1, Th17, T helper 22; Th22), CD8+ T cells (Tc17, Tc22) γδT cells, natural killer T (NKT) cells, lymphoid tissue inducer (LTi) cells, and certain NK cell subset.[ IL-22 has been related to PE. For instance, IL-22 concentration is significantly higher in PE patients group compared with the control group, resulting in the predominance of Th17- and Th22-mediated immunity in PE. This suggests that the immune imbalance among CD4 + T helper cells could lead to PE through placental ischemia.[ Also, Stefańska et al,[ showed that the IL-22, MDC, and IL2/IL-4 ratio can be used to discriminate between PE, gestation hypertension and healthy pregnancy. As for IL-17, only one SNP has been reported affecting the expression of IL-22 (rs2227485) involved in the development of PE in the Chinese Han population. Significant differences were found between PE patients and controls for this SNP in terms of genotypic frequencies (P < .001). Then rs2227485 was assessed under the dominant model of the C allele (CC/CT + TT genotype) or the recessive model of the T allele (TT/CC + CT genotype), and observed a significant difference under the recessive model of the T allele (P < .001, OR = 0.620, 95% CI 0.495–0.776).[

3. Discussions

Pathophysiology of PE is multifactorial, being the abnormal placentation a key factor that can trigger endothelial system dysfunction and dysregulation of the inflammatory process. Nevertheless, genetic aspects also play a very important role in the development of PE. PE is a complex and multi-symptomatic disease in which onset time, severity, and development can be a reflex of multiple genotypes. In this regard, considering that cytokines are involved in PE pathogenesis and that cytokine gene polymorphism may affect cytokine production it is obvious to seek for association between these candidate SNPs and PE. Until now, SNPs in IFN-γ, TNF-α, IL-4, IL-6, IL-10, IL-17A, and IL-22 have shown a clear association with the development, early-onset, and severity of PE. In this regard, Th1, Th2, and Th17 responses are modified by the presence of these SNPs, affecting processes such as placentation, control of inflammation, and vascular function (Fig. 2). Nevertheless, association studies have shown different results depending on sample size, diagnostic, and population. More extensive studies could help to have more accurate conclusions about how cytokine genotypes should be considered in clinical practice since PE remains a very serious public health problem.
Figure 2.

SNPs in IFN-γ, TNF-α, IL-4, IL-6, IL-10, IL-17A, and IL-22 have a clear association with the development, early-onset and severity of PE, modifying the Th1, Th2, and Th17 responses, affecting processes such as placentation, control of inflammation, and vascular function, which in turn affects organs such as kidney, liver and brain. This Altered production of immunoregulatory cytokines, a disbalance in angiogenic factors and maternal inflammatory response are responsible of PE severity. IFN-γ = interferon-gamma, IL-4 = interleukin 4, IL-6 = interleukin 6, IL-10 = interleukin 10, IL-17A = interleukin 17A, IL-22 = interleukin 22, PE = preeclampsia, SNP = single nucleotide polymorphism, Th1 = T helper 1, Th2 = T helper 2, Th17 = T helper 17.

SNPs in IFN-γ, TNF-α, IL-4, IL-6, IL-10, IL-17A, and IL-22 have a clear association with the development, early-onset and severity of PE, modifying the Th1, Th2, and Th17 responses, affecting processes such as placentation, control of inflammation, and vascular function, which in turn affects organs such as kidney, liver and brain. This Altered production of immunoregulatory cytokines, a disbalance in angiogenic factors and maternal inflammatory response are responsible of PE severity. IFN-γ = interferon-gamma, IL-4 = interleukin 4, IL-6 = interleukin 6, IL-10 = interleukin 10, IL-17A = interleukin 17A, IL-22 = interleukin 22, PE = preeclampsia, SNP = single nucleotide polymorphism, Th1 = T helper 1, Th2 = T helper 2, Th17 = T helper 17.

4. Conclusions

SNPs in IFN-γ, TNF-α, IL-4, IL-6, IL-10, IL-17A, and IL-22 have a clear association with the development, early-onset and severity of PE, modifying the Th1, Th2, and Th17 responses, affecting processes such as placentation, control of inflammation, and vascular function. Nevertheless, association studies have shown different results depending on sample size, diagnostic, and population.

Author contributions

Conceptualization: Carlos Mora-Palazuelos, Mercedes Bermúdez, Maribel Aguilar-Medina. Data curation: Carlos Mora-Palazuelos Mercedes Bermúdez. Formal analysis: Rosalío Ramos-Payan, Jose Geovanni Romero-Quintana. Investigation: Carlos Mora-Palazuelos, Maribel Aguilar-Medina, Alfredo Ayala-Ham. Methodology: Carlos Mora-Palazuelos, Maribel Aguilar-Medina, Alfredo Ayala-Ham. Writing – original draft: Carlos Mora-Palazuelos, Mercedes Bermúdez, Maribel Aguilar-Medina, Rosalío Ramos-Payan, Jose Geovanni Romero-Quintana. Writing – review & editing: Rosalío Ramos-Payan, Jose Geovanni Romero-Quintana.
  156 in total

Review 1.  Pre-eclampsia: pathophysiology and clinical implications.

Authors:  Graham J Burton; Christopher W Redman; James M Roberts; Ashley Moffett
Journal:  BMJ       Date:  2019-07-15

Review 2.  Redefining preeclampsia using placenta-derived biomarkers.

Authors:  Anne Cathrine Staff; Samantha J Benton; Peter von Dadelszen; James M Roberts; Robert N Taylor; Robert W Powers; D Stephen Charnock-Jones; Christopher W G Redman
Journal:  Hypertension       Date:  2013-03-04       Impact factor: 10.190

3.  Investigating the Association of IL-17A and IL-17F with Susceptibility to Pre-eclampsia in Iranian Women.

Authors:  Fahimah Anvari; Feryal Dabagh-Gorjani; Mohammad-Sadegh Soltani-Zangbar; Eskandar Kamali-Sarvestani; Zahra Malek-Hosseini; Behrouz Gharesi-Fard
Journal:  Iran J Immunol       Date:  2015-06       Impact factor: 1.603

4.  Therapeutic benefit of mesenchymal stem cells in pregnant rats with angiotensin receptor agonistic autoantibody-induced hypertension: Implications for immunomodulation and cytoprotection.

Authors:  Dan Zhang; Lihua Fu; Leilei Wang; Lin Lin; Lihong Yu; Lijun Zhang; Tao Shang
Journal:  Hypertens Pregnancy       Date:  2017-06-13       Impact factor: 2.108

5.  Association between Interleukin-10 gene polymorphisms and risk of early-onset preeclampsia.

Authors:  Limeng Song; Mei Zhong
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  Association of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in Iranian patients with pre-eclampsia.

Authors:  Mahroo Mirahmadian; Fathollah Kalantar; Golnaz Heidari; Lili Safdarian; Reza Mansouri; Ali Akbar Amirzargar
Journal:  Am J Reprod Immunol       Date:  2008-08       Impact factor: 3.886

7.  Interleukin-4 -590 (C>T), toll-like receptor-2 +2258 (G>A) and matrix metalloproteinase-9 -1562 (C>T) polymorphisms in pre-eclampsia.

Authors:  R Fraser; J J Walker; U V Ekbote; K L Martin; P McShane; N M Orsi
Journal:  BJOG       Date:  2008-07       Impact factor: 6.531

Review 8.  Interleukin-17A and Keratinocytes in Psoriasis.

Authors:  Masutaka Furue; Kazuhisa Furue; Gaku Tsuji; Takeshi Nakahara
Journal:  Int J Mol Sci       Date:  2020-02-13       Impact factor: 5.923

Review 9.  Cytokines as key players in the pathophysiology of preeclampsia.

Authors:  Raj Raghupathy
Journal:  Med Princ Pract       Date:  2013-08-15       Impact factor: 1.927

10.  Cytokine Imprint in Preeclampsia.

Authors:  Katarzyna Stefańska; Maciej Zieliński; Martyna Jankowiak; Dorota Zamkowska; Justyna Sakowska; Przemysław Adamski; Joanna Jassem-Bobowicz; Karolina Piekarska; Katarzyna Leszczyńska; Renata Świątkowska-Stodulska; Sebastian Kwiatkowski; Krzysztof Preis; Piotr Trzonkowski; Natalia Marek-Trzonkowska
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.